Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Trial Of Radioimmunotherapy, Reduced-Dose External Beam Craniospinal Radiation Therapy With IMRT Boost, And Chemotherapy For Patients With Standard-Risk Medulloblastoma

Trial Profile

A Trial Of Radioimmunotherapy, Reduced-Dose External Beam Craniospinal Radiation Therapy With IMRT Boost, And Chemotherapy For Patients With Standard-Risk Medulloblastoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs Monoclonal antibody 3F8 I-131 (Primary) ; Cisplatin; Lomustine; Vincristine
  • Indications Medulloblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Feb 2018 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
    • 23 Feb 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
    • 13 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top